CytomX Therapeutics Statistics
Share Statistics
CytomX Therapeutics has 157.54M
shares outstanding. The number of shares has increased by 2.8%
in one year.
| Shares Outstanding | 157.54M |
| Shares Change (YoY) | 2.8% |
| Shares Change (QoQ) | 2.35% |
| Owned by Institutions (%) | 54.9% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 191,865 |
| FTD / Avg. Volume | 3.55% |
Short Selling Information
The latest short interest is 17.73M, so 11.25% of the outstanding
shares have been sold short.
| Short Interest | 17.73M |
| Short % of Shares Out | 11.25% |
| Short % of Float | 11.69% |
| Short Ratio (days to cover) | 1.04 |
Valuation Ratios
The PE ratio is 2.73 and the forward
PE ratio is -6.11.
CytomX Therapeutics's PEG ratio is
0.
| PE Ratio | 2.73 |
| Forward PE | -6.11 |
| PS Ratio | 0.63 |
| Forward PS | 3.8 |
| PB Ratio | -190.73 |
| P/FCF Ratio | -1 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for CytomX Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25,
with a Debt / Equity ratio of -20.58.
| Current Ratio | 1.25 |
| Quick Ratio | 1.25 |
| Debt / Equity | -20.58 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | -0.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,160,529.41 |
| Profits Per Employee | $267,806.72 |
| Employee Count | 119 |
| Asset Turnover | 1.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 224K |
| Effective Tax Rate | 0.7% |
Stock Price Statistics
The stock price has increased by 57.74% in the
last 52 weeks. The beta is 2.12, so CytomX Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.12 |
| 52-Week Price Change | 57.74% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.05 |
| Relative Strength Index (RSI) | 72.19 |
| Average Volume (20 Days) | 5,400,357 |
Income Statement
In the last 12 months, CytomX Therapeutics had revenue of 138.1M
and earned 31.87M
in profits. Earnings per share was 0.38.
| Revenue | 138.1M |
| Gross Profit | 136.34M |
| Operating Income | 25M |
| Net Income | 31.87M |
| EBITDA | 25M |
| EBIT | 25M |
| Earnings Per Share (EPS) | 0.38 |
Full Income StatementBalance Sheet
The company has 38.05M in cash and 9.38M in
debt, giving a net cash position of 28.67M.
| Cash & Cash Equivalents | 38.05M |
| Total Debt | 9.38M |
| Net Cash | 28.67M |
| Retained Earnings | -691.58M |
| Total Assets | 98.5M |
| Working Capital | 36.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -86.23M
and capital expenditures -310K, giving a free cash flow of -86.54M.
| Operating Cash Flow | -86.23M |
| Capital Expenditures | -310K |
| Free Cash Flow | -86.54M |
| FCF Per Share | -1.02 |
Full Cash Flow StatementMargins
Gross margin is 98.72%, with operating and profit margins of 18.1% and 23.08%.
| Gross Margin | 98.72% |
| Operating Margin | 18.1% |
| Pretax Margin | 23.24% |
| Profit Margin | 23.08% |
| EBITDA Margin | 18.1% |
| EBIT Margin | 18.1% |
| FCF Margin | -62.66% |
